Smethurst Dominic 4

4 · Corbus Pharmaceuticals Holdings, Inc. · Filed Feb 4, 2026

AI-generated summary of this filing

Updated Feb 4, 2026

Corbus (CRBP) CMO Dominic Smethurst Sells 3,285 Shares

What Happened

Dominic Smethurst, Chief Medical Officer of Corbus Pharmaceuticals (CRBP), sold 3,285 shares on 2026-02-03. The reported weighted-average price was $8.09, with proceeds of approximately $26,575. This was a sale (not a purchase) and was performed to cover tax withholding obligations tied to RSU vesting.

Key Details

Transaction date: 2026-02-03; filing date: 2026-02-04 (appears timely).
Price: weighted average $8.09; actual sale prices ranged $8.01–$8.15 (multiple trades).
Shares sold: 3,285; reported proceeds ≈ $26,575.
Shares owned after transaction: the provided filing excerpt does not state total post-transaction beneficial ownership; footnote notes 86,265 unvested RSUs remain subject to each grant's vesting schedule.
Notable footnotes:
- F1: Sale was a mandatory "sell to cover" to satisfy tax withholding for RSU vesting (not a discretionary sell by the insider).
- F2: Price is a weighted average; detailed per-trade prices available on request.
- F3: Mentions 86,265 unvested RSUs still subject to vesting.

Context

"Sell to cover" transactions are routine tax-withholding events when RSUs vest; they generally do not signal an insider choosing to reduce a position for investment reasons. This filing reflects tax-related disposition rather than an independent sale decision.

Form 4

Period: 2026-02-03

Chief Medical Officer

Transactions

Sale
Common Stock, par value $0.0001 per share
[F1][F2][F3]
2026-02-03$8.09/sh−3,285$26,575→ 95,887 total

Footnotes (3)

[F1]The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units ("RSUs"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
[F2]The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.01 to $8.15. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F3]This amount includes 86,265 unvested RSUs subject to each grant's vesting schedule as previously reported.

Signature

/s/ Meghan Houghton, Attorney-in-Fact for Dominic Smethurst|2026-02-04

1 file